Portal de Periódicos da CAPES

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

2014; Elsevier BV; Volume: 89; Issue: 7 Linguagem: Inglês

10.1016/j.mayocp.2014.04.003

1942-5546

Stephen J. Russell, Mark J. Federspiel, Kah-Whye Peng, Caili Tong, David Dingli, William G. Morice, Val J. Lowe, Michael K. O’Connor, Robert A. Kyle, Nelson Leung, Francis K. Buadi, S. Vincent Rajkumar, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri,

Animal Virus Infections Studies

Abstract MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10 11 TCID 50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.